Yanan Zhu
Stock Analyst at Wells Fargo
(3.10)
# 1,221
Out of 5,136 analysts
88
Total ratings
45.83%
Success rate
2.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $5.04 | +118.25% | 4 | Jan 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $100 | $78.87 | +26.79% | 4 | Jan 5, 2026 | |
| QURE uniQure | Maintains: Overweight | $80 → $60 | $22.35 | +168.46% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $17 → $12 | $12.02 | -0.17% | 7 | Nov 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $50 → $45 | $22.80 | +97.37% | 7 | Nov 5, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $48 → $72 | $34.73 | +107.31% | 7 | Nov 3, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $7.73 | +158.73% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.22 | +80.18% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $31.92 | +40.98% | 1 | Aug 25, 2025 | |
| MGX Metagenomi Therapeutics | Maintains: Overweight | $16 → $12 | $1.73 | +593.64% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.08 | +131.48% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.42 | +252.11% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $2.38 | +488.24% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $72.54 | +3.39% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $35.41 | +97.68% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.13 | +142.13% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $33.16 | +20.63% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $56.89 | +14.26% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.10 | +229.67% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.43 | +823.79% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.74 | +16,323.36% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $799.33 | -59.22% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.24 | +583.59% | 2 | Oct 29, 2020 |
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $5.04
Upside: +118.25%
Ionis Pharmaceuticals
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $78.87
Upside: +26.79%
uniQure
Nov 12, 2025
Maintains: Overweight
Price Target: $80 → $60
Current: $22.35
Upside: +168.46%
Intellia Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $17 → $12
Current: $12.02
Upside: -0.17%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $22.80
Upside: +97.37%
RAPT Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $48 → $72
Current: $34.73
Upside: +107.31%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $7.73
Upside: +158.73%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.22
Upside: +80.18%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $31.92
Upside: +40.98%
Metagenomi Therapeutics
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.73
Upside: +593.64%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.08
Upside: +131.48%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.42
Upside: +252.11%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.38
Upside: +488.24%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $72.54
Upside: +3.39%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $35.41
Upside: +97.68%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.13
Upside: +142.13%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $33.16
Upside: +20.63%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $56.89
Upside: +14.26%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $9.10
Upside: +229.67%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.43
Upside: +823.79%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.74
Upside: +16,323.36%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $799.33
Upside: -59.22%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.24
Upside: +583.59%